Satellos Bioscience Inc. (MSLE) Stock Score, Valuation & Financial Research

Satellos Bioscience Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MSLE

Satellos Bioscience Inc. does not currently have a complete Wall Street Score. The stored market price is USD 8.24. These figures are a research snapshot, not a buy or sell recommendation.

What Satellos Bioscience Inc. does

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to treat degenerative muscle diseases. The company generates no product revenue and currently funds its operations primarily through equity financings and capital raises to support the research and development of its proprietary muscle regeneration platform.

Products and services

  • The company is developing a pipeline of small-molecule drug candidates, including its lead candidate Forazapadin (SAT-3247), designed to promote the body's innate muscle repair and regeneration process.

Brands and product families

  • Forazapadin (SAT-3247) — Lead drug candidate for the treatment of degenerative muscle diseases. Source

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various unnamed third-party contract research organizations to conduct preclinical and clinical studies. Source
  • Contract Development and Manufacturing Organizations (CDMOs) — The company relies on unnamed third-party manufacturers for the production of its drug candidates for clinical trials. Source

Business strengths to evaluate

  • Proprietary MyoReGenX platform for muscle regeneration Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on the success of a limited number of drug candidates Source
  • Requirement for additional capital to fund future operations Source

Sources: Company research source · Forazapadin (SAT-3247)

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MSLE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 8.24
Market capitalization:
10.62M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -34.31M
Free cash flow:
USD -23.6M
Cash:
USD 7.38M
Total debt:
USD 0.00
EPS:
USD -1.92

What stands out

  • Free cash flow is USD -23.6M, negative for the stored period.
  • The balance sheet shows USD 7.38M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.38M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MSLE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MSLE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MSLE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MSLE to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MSLE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research MSLE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.